Wei Xin, Chen Zhiyu, Yang Xiaoyan, Wu Taixiang
Department of Ophthalmology & Ophthalmic Laboratories, West China Hospital, Sichuan University, Chengdu, China, 610041.
Cochrane Database Syst Rev. 2009 Oct 7(4):CD004520. doi: 10.1002/14651858.CD004520.pub6.
Esophageal cancer is the seventh leading cause of cancer death worldwide. Traditional Chinese herbal medicines are sometimes used as an adjunct to radiotherapy or chemotherapy for this type of cancer.
To assess the efficacy and possible adverse effects of the addition of Chinese herbal medicines to treatment with radiotherapy or chemotherapy for esophageal cancer.
We searched the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Trials Register, The Cochrane Library, MEDLINE, EMBASE, AMED (Allied and Complementary Medicine Database), CBM (Chinese Biomedical Database), China National Knowledge Infrastructure, the Chinese Cochrane Centre Controlled Trials Register and CISCOM (The Research Council for Complementary Medicine) (up to 10 July, 2008). Databases of ongoing trials, the Internet and reference lists were also searched.
Randomised controlled trials comparing the use of radiotherapy or chemotherapy with and without the addition of Chinese herbal medicines.
At least two review authors extracted data and assessed trial quality.
We identified 43 trials which claimed to use random allocation. The first authors of all the RCTs we initially identified were contacted by telephone and we discovered that the authors had misunderstood the randomisation procedure. Using this new information, we reassigned all the identified RCTs as non-randomised trials. Because we identified no authentic randomised controlled trials, we were unable to perform a meta-analysis.
AUTHORS' CONCLUSIONS: We were unable to find any evidence from RCTs on the effectiveness of TCM in the treatment of esophageal cancer. New trials should be carried out and we recommend that they are large scaled, correctly randomised and that the assessors of the results are blinded to the conditions of allocation.
食管癌是全球癌症死亡的第七大主要原因。传统中草药有时被用作这种癌症放疗或化疗的辅助手段。
评估添加中草药到食管癌放疗或化疗治疗中的疗效及可能的不良反应。
我们检索了Cochrane上消化道和胰腺疾病组试验注册库、Cochrane图书馆、MEDLINE、EMBASE、AMED(联合与补充医学数据库)、CBM(中国生物医学数据库)、中国知网、中国Cochrane中心对照试验注册库和CISCOM(补充医学研究理事会)(截至2008年7月10日)。还检索了正在进行的试验数据库、互联网和参考文献列表。
比较使用或不使用中草药的放疗或化疗的随机对照试验。
至少两名综述作者提取数据并评估试验质量。
我们识别出43项声称采用随机分配的试验。我们通过电话联系了所有最初识别出的RCT的第一作者,发现作者误解了随机化程序。利用这些新信息,我们将所有识别出的RCT重新归类为非随机试验。由于我们未识别出任何真实的随机对照试验,因此无法进行荟萃分析。
我们无法从随机对照试验中找到任何关于中医治疗食管癌有效性的证据。应开展新的试验,我们建议试验规模要大、随机化正确且结果评估者对分配情况不知情。